Compare TWLO & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWLO | RVMD |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 5587 | 883 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 19.2B |
| IPO Year | N/A | N/A |
| Metric | TWLO | RVMD |
|---|---|---|
| Price | $117.77 | $96.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 17 |
| Target Price | ★ $144.52 | $120.47 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $8.21 | $411.49 |
| P/E Ratio | $526.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.90 | $34.00 |
| 52 Week High | $145.90 | $124.49 |
| Indicator | TWLO | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 48.20 |
| Support Level | $115.43 | $93.39 |
| Resistance Level | $134.76 | $101.00 |
| Average True Range (ATR) | 6.40 | 3.06 |
| MACD | -0.64 | 0.21 |
| Stochastic Oscillator | 19.30 | 50.90 |
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.